Detalhe da pesquisa
1.
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Oncologist
; 29(5): e681-e689, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38241181
2.
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Cancer Sci
; 114(2): 606-618, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36169649
3.
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Cancer Immunol Immunother
; 72(6): 1699-1707, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36617602
4.
A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.
BMC Cancer
; 19(1): 528, 2019 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31151425
5.
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
BMC Cancer
; 18(1): 1241, 2018 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30537950
6.
Cytokine Release Syndrome with Relative Adrenal Insufficiency Induced by Ipilimumab and Nivolumab Combination Therapy for Clear Cell Renal Cell Carcinoma.
Intern Med
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38432959
7.
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Target Oncol
; 19(3): 411-421, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467958
8.
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study.
JTO Clin Res Rep
; 5(3): 100644, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38444594
9.
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Cancer Lett
; 587: 216692, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342232
10.
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Front Immunol
; 15: 1348034, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38464519
11.
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Front Oncol
; 14: 1303543, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344209
12.
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
J Cancer Res Clin Oncol
; 149(6): 2475-2482, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737092
13.
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Target Oncol
; 18(5): 657-665, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37610516
14.
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.
Cancers (Basel)
; 15(5)2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900334
15.
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
JTO Clin Res Rep
; 4(4): 100493, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37025120
16.
Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non-small cell lung cancer.
Cancer Med
; 12(8): 9097-9105, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36707978
17.
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Drugs Aging
; 40(6): 563-571, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37145245
18.
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study.
Cancers (Basel)
; 15(17)2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37686634
19.
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Thorac Cancer
; 14(11): 1004-1011, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36866788
20.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
JAMA Netw Open
; 6(7): e2322915, 2023 07 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37432682